Healthtech funding in Q1 2020
European Healthtech startup funding raised during Q1 2020.
In Q1 2020, 107 European Healthtech companies closed 109 funding rounds and raised €875M in equity funding (excluding debt and grants), down 32.1% versus Q1 2019. Israel led by capital raised, and Ananda Impact Ventures was the most active investor. Data as of 20 Nov 2026.
Equity funding
€875M
-32.1% vs Q1 2019 · excl. debt & grants
Funding rounds
109
-5.2% vs Q1 2019
Companies
107
Top country
Israel
Rank among sectors
#6
5.8% of sector funding
Top-10 round share
43.6%
of disclosed capital
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q1 2020 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €347M | 54 |
| Feb | €365M | 37 |
| Mar | €164M | 18 |
Top countries
by € raisedHealthtech — top countries by capital, Q1 2020 — interactive chart.
Data table
| Healthtech — top countries by capital, Q1 2020 | |
|---|---|
| Israel | €205M |
| UK | €198M |
| France | €127M |
| Germany | €77M |
| Netherlands | €59M |
| Switzerland | €52M |
| Sweden | €44M |
| Belgium | €35M |
Stage mix
by € raisedHealthtech — stage mix, Q1 2020 — interactive chart.
Data table
| Healthtech — stage mix, Q1 2020 | |
|---|---|
| Other | €291M |
| Series B | €229M |
| Series A | €163M |
| Series C | €96M |
| Seed | €56M |
| Series D+ | €28M |
| Early VC | €12M |
| Grant | €645k |
Exits & M&A
20 Acquisition20 exits · €1.1B disclosed.
| Polyplus-Transfection | Acquisition | Feb 2020 | €460M |
| Galecto | Acquisition | Jan 2020 | €398M |
| MaSTherCell | Acquisition | Feb 2020 | €285M |
Top deals
largest disclosed rounds in Q1 2020| Company | Stage | Date | Amount |
|---|---|---|---|
| Compugen | Other | Mar 2020 | €68M |
| Cera | Other | Feb 2020 | €65M |
| Dynacure | Series C | Feb 2020 | €50M |
| K Health | Series C | Feb 2020 | €44M |
| Northsea Therapeutics | Series B | Jan 2020 | €36M |
| Evonetix | Series B | Feb 2020 | €27M |
| ŌURA | Series B | Mar 2020 | €25M |
| Merantix | Series A | Jan 2020 | €25M |
| Nanox Imaging | Other | Jan 2020 | €23M |
| Oncodna | Series B | Feb 2020 | €19M |
| Oviva | Series B | Jan 2020 | €19M |
| Citryll | Other | Feb 2020 | €19M |
| Alderaan Biotechnology | Series A | Jan 2020 | €19M |
| Geneuro | Other | Jan 2020 | €18M |
| Temedica | Series B | Jan 2020 | €17M |
Top investors
most active in Q1 2020, by deal count- Ananda Impact Ventures2 deals
- High-Tech Gründerfonds (HTGF)2 deals
- Kamet Ventures2 deals
- NPIF – Mercia Equity Finance2 deals
- OCCIDENT2 deals
- Praetura Ventures2 deals
- 14W1 deals
- Acton Capital Partners1 deals
- Advent France Biotechnology (AFB) and Medicxi1 deals
- Alven Capital1 deals